Results 161 to 170 of about 21,736 (211)

Intravenous ⁶⁴zn-Aspartate Mitigates Neuroinflammation and Motor Dysfunction in an Lps-Induced Parkinson's Disease Rat Model. [PDF]

J Neuroimmune Pharmacol
Temnik M, Rudyk M, Balakin A, Gurin S, Dovbynchuk T, Byshovets R, Dzubenko N, Tolstanova G, Skivka L.   +8 more
europepmc   +1 more source

A Highly Potent Apomorphine Derivative Enhancing Neurite Outgrowth via Nrf2 Activation. [PDF]

Antioxidants (Basel)
Ishima T, Osaka H, Nagai R, Aizawa K.
europepmc   +1 more source

Optimizing Device-Aided Therapies in Advanced Parkinson's Disease: A Case Series on Continuous Subcutaneous Apomorphine Infusion in Challenging Scenarios. [PDF]

J Mov Disord
De Leon APR, Bhidayasiri R, Phokaewvarangkul O.   +2 more
europepmc   +1 more source

Editorial: Emerging challenges in companion animal toxicology. [PDF]

Front Vet Sci
Bates N, Hovda LR, Seljetun KO.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Glucuronidation of apomorphine

Life Sciences, 2000
Apomorphine, a dopaminergic receptor agonist, is largely used in the therapy of Parkinson's disease. In this study, we characterized the glucuronidation of apomorphine and other catechols in rat liver and brain microsomes, using UDP-[U-14C]glucuronic acid and separation of the glucuronides formed by a thin layer chromatographic method.
R S, El-Bachá, S, Leclerc, P, Netter, J, Magdalou, A, Minn   +4 more
openaire   +2 more sources

Pharmacology and Neurochemistry of Apomorphine

1978
Publisher Summary This chapter discusses the pharmacology and neurochemistry of apomorphine. Apomorphine was first employed as a powerful emetic agent. Apomorphine can be obtained by the acid-catalyzed rearrangement of morphine and by total synthesis.
DI CHIARA, GAETANO, GESSA GL
openaire   +2 more sources

Apomorphine

Reactions Weekly, 2020
  +5 more sources

Apomorphine

Reactions Weekly, 2021
openaire   +2 more sources

Apomorphine

Reactions Weekly, 2011
  +4 more sources